BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced that the new manufacturing facility in Israel has successfully met the Israeli Ministry of Health's ISO9001 and ISO22000 (HACCP) certification requirements ahead of time.
The company noted that the ISO9001 certification covers internationally recognized standards for quality assurance and management, and the ISO22000 (HACCP) certification ensures that the required quality control and quality management systems are in place across the end-to-end manufacturing process to ensure the highest product safety levels. These two certifications are critical steps required prior to obtaining the GMP (Good Manufacturing Practices) certification from the Israeli Ministry of Health.
In a statement, Kobi Rosenzweig, VP of Operations at BioHarvest Sciences said: "I am delighted with the Company's ability to successfully pass the internationally recognized stringent quality requirements on its first attempt. Considering the speed at which this factory was built, this achievement is a testimony to the quality of the team and the ingenuity of the BioFarming technology. I thank our manufacturing partner Sugart and especially Ori Hahn, their CEO, for all the efforts exerted to deliver on such an aggressive schedule."
READ: BioHarvest Sciences says it has successfully scaled its cannabis cells with trichomes production by a factor of 250 times
Despite the challenges caused by the coronavirus (COVID19) to the global supply chain, the new factory was built in 12 months. The facility will have the capacity to produce over 20 tons/year of VINIA as well as other polyphenol-based products the company has in its innovation pipeline.
Pilot production of VINIA in the new facility is expected to begin by the end of September 2021, and the capacity will be steadily increased each month to meet the growing demands of VINIA's D2C and B2B business in Israel, USA and other global markets.
Ilan Sobel, CEO of BioHarvest Sciences added: "The manufacturing arm of BioHarvest is an integral part of the Company's biotech vision. As a biotech innovator we will continue to develop and manufacture new products across multiple verticals. We have implemented the industrial manufacturing blueprint of our BioFarming technology in 12 months. This accomplishment gives me enormous confidence in our ability to scale our technology as we add on new verticals, (as in the case of Cannabis), and to build manufacturing plants closer to local markets such as North America, if required."
Based in Vancouver British Columbia, BioHarvest Sciences is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself.
The company's technology is non-GMO and has already been validated by VINIA, the red grapes cells functional food/dietary supplement produced and sold by the company. It plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA and other Super Fruit Nutraceutical products.
Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences' objective is to become a leading supplier of cannabis for both medicinal and legal recreational purposes.
Contact the author at jon.hopkins@proactiveinvestors.com